Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Novartis obtains worldwide development and commercialization rights of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer and also its preclinical AR-V7 program.
Lead Product(s): Luxdegalutamide,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: ARV-766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,160.0 million Upfront Cash: $150.0 million
Deal Type: Licensing Agreement April 11, 2024
Details:
ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target LRRK2. It is being evaluated for the treatment of parkinson’s disease and progressive supranuclear palsy.
Lead Product(s): ARV-102
Therapeutic Area: Neurology Product Name: ARV-102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor. It is being evaluated in phase 3 clinical trials for the treatment of patients with ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
Arvinas expects to use net proceeds to advance its clinical development programs and preclinical pipeline, including ARV-471 (vepdegestrant), an investigational orally bioavailable PROTAC® protein degrader.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 27, 2023
Details:
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
The collaboration aims to evaluate the novel combination of CT7001 (samuraciclib), an oral, first-in-class inhibitor of CDK7, and Arvinas’ ARV-471 (vepdegestrant), an investigational oral PROTAC® estrogen receptor protein degrader being developed in metastatic breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Carrick Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2023
Details:
ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.
Lead Product(s): Luxdegalutamide
Therapeutic Area: Oncology Product Name: ARV-766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
ARV-471 is an investigational, orally-bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Lead Product(s): ARV-471,Palbociclib
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
Initial goal of collaboration is to develop FoundationOne® liquid CDx as a companion diagnostic for Bavdegalutamide (ARV-110), Arvinas’ investigational Androgen receptor-targeting PROTAC® protein degrader.
Lead Product(s): Bavdegalutamide
Therapeutic Area: Oncology Product Name: ARV-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Foundation Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 05, 2022
Details:
Under the terms of the agreement, Arvinas will leverage GNS’ Gemini Virtual Patient models to better understand the biology of the underlying disease, how it progresses, and how potential drugs might perform at the individual patient level.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: GNS Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 09, 2022